HOME Top Market Reports Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020

Cancer Diagnostics Market by Technology (ELISA, ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET, Ultrasound, Mammography), Biopsy), Application (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma) - Forecast to 2020

By: marketsandmarkets.com
Publishing Date: June 2015
Report Code: MD 3480

Discount on Reports  

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The global cancer diagnostics market is segmented on the basis of technology, application, and region. Based on technology, this market is categorized into platform-based and instrument-based. The instrument-based segment is expected to account for a major share of this market, in 2015. The platform-based technology is further segmented into next-generation sequencing, microarrays, PCR, flow cytometry, in situ hybridization, immunohistochemistry, and others. Instrument-based cancer diagnostics is further segmented into imaging systems and biopsy. On the basis of geography, the market is divided into North America, Europe, Asia, and the Rest of World (RoW: Latin America, Pacific countries, and Middle East and Africa).

Technological advancements in various fields such as biomarkers, imaging, biopsy, endoscopy; growing number of cancer cases, rapidly rise in geriatric population, awareness initiatives by governments, and increasing government funding are major factors driving the market growth. However, high capital investment and low benefit-cost ratio of biomarkers and dearth of skilled professionals pose restraints to the growth of this market. Improving healthcare infrastructure in emerging countries and growing demand of companion diagnostics offer growth opportunities for the this market.

Some of the major players in the global cancer diagnostics market include Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (Denmark), Becton, Dickinson and Company (U.S.), GE Healthcare (U.K.), QIAGEN N.V.  (Netherlands), Abbott Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), Philips Healthcare (U.K.), and C.R. Bard, Inc. (U.S.).

Scope of the Report

This research report categorizes the cancer diagnostics market into the following segments and subsegments:

Cancer Diagnostics Market, by Product

  • Platform-based
    • Next-generation Sequencing
    • Microarrays
    • PCR
    • Flow Cytometry
    • In situ Hybridization
    • Immunohistochemistry
    • Others
  • Instrument-based
    • Imaging Instruments
      • MRI
      • CT
      • PET
      • Ultrasound
      • Mammography
    • Biopsy

Cancer Diagnostics Market, by Application

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma
  • Others

Cancer Diagnostics Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • EU-5
    • Rest of Europe (RoE)
  • Asia
    • Japan
    • China
    • India
    • Rest of Asia (RoA)
  • Rest of the World (RoW)

Table of Contents

1 Introduction (Page No. - 15)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 19)
           2.1.1 Research Methodology Steps
           2.1.2 Secondary and Primary Research Methodology
                    2.1.2.1 Secondary Research
                    2.1.2.2 Key Data From Secondary Sources
                    2.1.2.3 Primary Research
                    2.1.2.4 Key Industry Insights
           2.1.5 Key Data From Primary Sources
           2.1.6 Key Insights From Primary Sources
           2.1.7 Market Size Estimation Methodology
           2.1.8 Market Forecast Methodology
           2.1.9 Market Data Validation and Triangulation
           2.1.10 Assumptions for the Study

3 Executive Summary (Page No. - 32)
    3.1 Introduction
    3.2 Current Scenario
    3.3 Future Outlook
    3.4 Conclusion

4 Premium Insights (Page No. - 38)
    4.1 Global Cancer Diagnostics Market
    4.2 Regional Snapshot of the Cancer Diagnostics Market
    4.3 Cancer Diagnostics Market, By Technology (2015 vs. 2020)

5 Market Overview (Page No. - 42)
    5.1 Key Findings
    5.2 Introduction
    5.3 Market Dynamics
           5.3.1 Drivers
                    5.3.1.1 Rising Prevalence of Cancer
                    5.3.1.2 Technological Advancements
                    5.3.1.3 Initiatives Undertaken By Governments and Global Health Organizations to Spread Awareness About Cancer
                    5.3.1.4 Growth in the Number of Private Diagnostic Centers
                    5.3.1.5 Public-Private Partnerships to Enhance the Infrastructure of Diagnostic Imaging Centers
                    5.3.1.6 Fda Support for Biomarker Development
                    5.3.1.7 Launch of New Flow Cytometry Reagents for Diagnostics and Drug Discovery
           5.3.2 Restraints
                    5.3.2.1 High Capital Investments & Low Benefit-Cost Ratio for Biomarkers
                    5.3.2.2 Shortage of Helium
                    5.3.2.3 High Cost of Diagnostic Imaging Systems Affecting Their Rate of Adoption in Emerging Markets
                    5.3.2.4 Risk of High Radiation Exposure Likely to Limit the Usage of CT Scanners
                    5.3.2.5 Dearth of Skilled and Experienced Personnel
           5.3.3 Opportunities
                    5.3.3.1 Personalized Medicine
                    5.3.3.2 Development of Mass Cytometry and the Combination of Cell-And Bead-Based Flow Cytometry Technologies
                    5.3.3.3 Companion Diagnostics
                    5.3.3.4 Improving Healthcare Infrastructure in Emerging Markets
                    5.3.3.5 Miniaturized and Technologically Advanced Devices
           5.3.4 Challenges
                    5.3.4.1 Stringent Regulatory Guidelines
                    5.3.4.2 Hospital Budget Cuts A Key Challenge to Market Players
                    5.3.4.3 Increasing Adoption of Refurbished Diagnostic Imaging Systems

6 Global Cancer Diagnostics Market, By Technology (Page No. - 60)
    6.1 Introduction
    6.2 Platform-Based Diagnostics
           6.2.1 Polymerase Chain Reaction (PCR)
           6.2.2 in Situ Hybridization (ISH)
           6.2.3 Immunohistochemistry (IHC)
           6.2.4 Next-Generation Sequencing (NGS)
           6.2.5 Microarrays
           6.2.6 Flow Cytometry
           6.2.7 Other Technologies
    6.3 Instrument-Based
           6.3.1 Diagnostic Imaging
                    6.3.1.1 Magnetic Resonance Imaging (MRI)
                    6.3.1.2 Computed Tomography (Ct)
                    6.3.1.3 Positron Emission Tomography (PET)
                               6.3.1.3.1 Standalone Positron Emission Tomography
                               6.3.1.3.2 Hybrid Positron Emission Tomography
                    6.3.1.4 Mammography
                    6.3.1.5 Ultrasound
           6.3.2 Biopsies

7 Global Cancer Diagnostics Market, By Application (Page No. - 84)
    7.1 Introduction
           7.1.1 Breast Cancer
           7.1.2 Lung Cancer
           7.1.3 Colorectal Cancer
           7.1.4 Melanoma
           7.1.5 Other Cancers

8 Market, By End User (Page No. - 93)

9 Cancer Diagnostics Market, By Region (Page No. - 95)
    9.1 Introduction
    9.2 North America
           9.2.1 U.S.
                    9.2.1.1 Government Initiatives
                    9.2.1.2 Increase in Cancer Incidence
           9.2.2 Canada
                    9.2.2.1 High Incidence of Cancer
                    9.2.2.2 Government Funding
    9.3 Europe
           9.3.1 Funding for Cancer Diagnostics Research
           9.3.2 Eu-5 (U.K., Germany, France, Italy, Spain)
                    9.3.2.1 Strong Government Support
                    9.3.2.2 Research Collaborations
                    9.3.2.3 Increase in Diagnostic Imaging Centers
                    9.3.2.4 Rising Public and Private Investments
           9.3.3 Rest of Europe (RoE)
                    9.3.3.1 Aging Population
                    9.3.3.2 Conferences Boosting Awareness
                    9.3.3.3 Government Investments in Russia
    9.4 Asia
                    9.4.1.1 China
                               9.4.1.1.1 Expansion of International Players
                               9.4.1.1.2 Aging Population and Increasing Cancer Incidence
                    9.4.1.2 Japan
                               9.4.1.2.1 Aging Population and High Healthcare Expenditure in Japan
                    9.4.1.3 India
                               9.4.1.3.1 Increasing Focus of International Players on India
                    9.4.1.4 Rest of Asia
                               9.4.1.4.1 Presence of International Players Boosting Market Growth
    9.5 Rest of the World (RoW)
                    9.5.1.1 Government Initiatives Boosting Demand for Cancer Diagnostics
                    9.5.1.2 Aging Population, Presence of International Players
                    9.5.1.3 Increase in Cancer Incidences and Rising Government Expenditure
                    9.5.1.4 Government Initiatives to Improve Healthcare Infrastructure

10 Competitive Landscape (Page No. - 138)
     10.1 Overview
     10.2 Market Share Analysis
     10.3 Competitive Situation and Trends
             10.3.1 Collaborations/Agreements/Partnerships/Alliances
             10.3.2 New Product Launches
             10.3.3 Acquisitions
             10.3.4 Expansion
             10.3.5 Others

11 Company Profiles (Page No. - 153)
     11.1 Introduction
     11.3 Becton, Dickinson and Company
             11.3.1 Business Overview
             11.3.2 Product Portfolio
             11.3.3 Key Strategy
             11.3.4 Recent Developments
     11.4 GE Healthcare (A Subsidiary of General Electric Company)
             11.4.1 Business Overview
             11.4.2 Product Portfolio
             11.4.3 Key Strategy
             11.4.4 Recent Developments
     11.5 Abbott
             11.5.1 Business Overview
             11.5.2 Product Portfolio
             11.5.3 Key Strategy
             11.5.4 Recent Developments
     11.6 Roche
             11.6.1 Business Overview
             11.6.2 Product Portfolio
             11.6.3 Key Strategy
             11.6.4 Recent Developments
     11.7 Thermo Fisher Scientific, Inc.
             11.7.1 Business Overview
             11.7.2 Thermo Fisher Scientific, Inc.: Company Snapshot
             11.7.3 Product Portfolio
             11.7.4 Key Strategy
             11.7.5 Recent Developments
     11.8 Agilent Technologies, Inc.
             11.8.1 Business Overview
             11.8.2 Agilent Technologies, Inc.: Company Snapshot
             11.8.3 Product Portfolio
             11.8.4 Key Strategy
             11.8.5 Recent Developments
     11.9 Illumina, Inc.
             11.9.1 Business Overview
             11.9.2 Product Portfolio
             11.9.3 Key Strategy
             11.9.4 Recent Developments
     11.10 Siemens Healthcare
             11.10.1 Business Overview
             11.10.2 Product Portfolio
             11.10.3 Key Strategy
             11.10.4 Recent Developments
     11.11 C.R. Bard, Inc.
             11.11.1 Business Overview
             11.11.2 Product Portfolio
             11.11.3 Key Strategy
             11.11.4 Recent Developments

12 Appendix (Page No. - 190)
     12.1 Discussion Guide
     12.2 Available Customizations
     12.3 Related Reports
     12.4 Introducing RT: Real-Time Market Intelligence


List of Tables (89 Tables)

Table 1 Rising Prevalence of Cancer is Driving the Growth of the Cancer Diagnostics Market
Table 2 High Capital Investment Restraining the Growth of this Market
Table 3 Emerging Markets Present an Array of Opportunities for the Growth of this Market
Table 4 Stringent Regulatory Guidelines are A Major Challenge in the Cancer Diagnostics Market
Table 5 Global Cancer Diagnostics Market Size, By Technology, 20132020 ($Million)
Table 6 Global Market Size, By Technology, 20132020 ($Million)
Table 7 Market Size for Platform-Based Diagnostics, By Region, 20132020 ($Million)
Table 8 Global Cancer Diagnostics Market Size for PCR, By Region, 20132020 ($Million)
Table 9 Global Cancer Diagnostics Market Size for PCR, By Application, 20132020 ($Million)
Table 10 Cancer Diagnostics Market Size for in Situ Hybridization, By Region, 2013-2020 ($Million)
Table 11 Global Market Size for in Situ Hybridization, By Application, 20132020 ($Million)
Table 12 Market Size for Immunohistochemistry, By Region, 20132020 ($Million)
Table 13 Global Cancer Diagnostics Market Size for Immunohistochemistry, By Application, 20132020 ($Million)
Table 14 Market Size for NGS, By Region, 20132020 ($Million)
Table 15 Global Market Size for NGS, By Application, 20132020 ($Million)
Table 16 Cancer Diagnostics Market Size for Microarrays, By Region, 20132020 ($Million)
Table 17 Global Market Size for Microarrays, By Application, 20132020 ($Million)
Table 18 Cancer Diagnostics Market Size for Flow Cytometry, By Region, 20132020 ($Million)
Table 19 Global Market Size for Flow Cytometry, By Application,  20132020 ($Million)
Table 20 Market Size for Other Technologies, By Region, 20132020 ($Million)
Table 21 Global Market Size for Other Technologies, By Application, 20132020 ($Million)
Table 22 Global Market Size, By Technology, 20132020 ($Million)
Table 23 Cancer Diagnostics Market Size for Diagnostic Imaging, By Product, 20132020 ($Million)
Table 24 Market Size for Diagnostic Imaging, By Region, 20132020 ($Million)
Table 25 Global Market Size for Imaging, By Application, 20132020 ($Million)
Table 26 Cancer Diagnostics Market Size for MRI, By Region, 20132020 ($Million)
Table 27 Cancer Diagnostics Market Size for CT, By Region, 20132020 ($Million)
Table 28 Market Size for PET, By Product, 20132020 ($Million)
Table 29 Cancer Diagnostics Market Size for PET, By Region, 20132020 ($Million)
Table 30 Cancer Diagnostics Market Size for Standalone PET, By Region, 20132020 ($Million)
Table 31 Market Size for Hybrid PET, By Region, 20132020 ($Million)
Table 32 Market Size for Mammography, By Region, 20132020 ($Million)
Table 33 Cancer Diagnostics Market Size for Ultrasound, By Region, 20132020 ($Million)
Table 34 Cancer Diagnostics Market Size for Biopsy, By Region, 20132020 ($Million)
Table 35 Global Market Size for Biopsy, By Application, 20132020 ($Million)
Table 36 Global Market Size, By Application, 20132020 ($Million)
Table 37 Market Size for Breast Cancer, By Region, 20132020 ($Million)
Table 38 Cancer Diagnostics Market Size for Lung Cancer, By Region, 20132020 ($Million)
Table 39 Market Size for Colorectal Cancer, By Region, 20132020 ($Million)
Table 40 Market Size for Melanoma, By Region, 20132020 ($Million)
Table 41 Cancer Diagnostics Market Size for Other Cancers, By Region, 20132020 ($Million)
Table 42 North America Market, By Country, 20132020 ($Million)
Table 43 North America: Market, By Technology, 20132020 ($Million)
Table 44 North America: Cancer Diagnostics Platform-Based Market, By Technology, 20132020 ($Million)
Table 45 North America: Cancer Diagnostics Instrument-Based Market, By Technology, 20132020 ($Million)
Table 46 North America: Market, By Application, 20132020 ($Million)
Table 47 U.S.: Market, By Technology, 20132020 ($Million)
Table 48 U.S.: Cancer Diagnostics Platform-Based Market, By Technology, 20132020 ($Million)
Table 49 U.S.: Cancer Diagnostics Instrument-Based Market, By Technology, 20132020 ($Million)
Table 50 Canada: Market, By Technology, 20132020 ($Million)
Table 51 Canada: Cancer Diagnostics Platform-Based Market, By Technology, 20132020 ($Million)
Table 52 Canada: Cancer Diagnostics Instrument-Based Market, By Technology, 20132020 ($Million)
Table 53 Europe: Market, By Region, 20132020 ($Million)
Table 54 Europe: Cancer Diagnostics Market, By Technology, 20132020 ($Million)
Table 55 Europe: Cancer Diagnostics Platform-Based Market, By Technology, 20132020 ($Million)
Table 56 Europe: Cancer Diagnostics Instrument Market, By Technology, 20132020 ($Million)
Table 57 Europe: Cancer Diagnostics Market, By Application, 20132020 ($Million)
Table 58 EU-5: Market, By Technology, 20132020 ($Million)
Table 59 EU-5: Cancer Diagnostics Platform-Based Market, By Technology, 20132020 ($Million)
Table 60 EU-5: Cancer Diagnostics Instrument-Based Market, By Technology, 20132020 ($Million)
Table 61 RoE: Market, By Technology, 20132020 ($Million)
Table 62 RoE: Cancer Diagnostics Platform-Based Market, By Technology, 20132020 ($Million)
Table 63 RoE: Cancer Diagnostics Instrument-Based Market, By Technology, 20132020 ($Million)
Table 64 Asia: Market, By Country, 20132020 ($Million)
Table 65 Asia: Market, By Technology, 20132020 ($Million)
Table 66 Asia: Cancer Diagnostics Platform-Based Market, By Technology, 20132020 ($Million)
Table 67 Asia: Cancer Diagnostics Instrument-Based Market, By Technology, 20132020 ($Million)
Table 68 Asia: Market, By Application, 20132020 ($Million)
Table 69 China: Market, By Technology, 20132020 ($Million)
Table 70 China: Cancer Diagnostics Platform-Based Market, By Technology, 20132020 ($Million)
Table 71 China: Cancer Diagnostics Instrument-Based Market, By Technology, 20132020 ($Million)
Table 72 Japan: Market, By Technology, 20132020 ($Million)
Table 73 Japan: Cancer Diagnostics Platform-Based Market, By Technology, 20132020 ($Million)
Table 74 Japan: Cancer Diagnostics Instrument-Based Market, By Technology, 20132020 ($Million)
Table 75 India: Market, By Technology, 20132020 ($Million)
Table 76 India: Cancer Diagnostics Platform-Based Market, By Technology, 20132020 ($Million)
Table 77 India: Cancer Diagnostics Instrument-Based Market, By Technology, 20132020 ($Million)
Table 78 RoA: Market, By Technology, 20132020 ($Million)
Table 79 RoA: Cancer Diagnostics Platform-Based Market, By Technology, 20132020 ($Million)
Table 80 RoA: Cancer Diagnostics Instrument-Based Market, By Technology, 20132020 ($Million)
Table 81 RoW: Market, By Technology, 20132020 ($Million)
Table 82 RoW: Cancer Diagnostics Platform-Based Market, By Technology, 20132020 ($Million)
Table 83 RoW: Cancer Diagnostics Instrument-Based Market, By Technology, 20132020 ($Million)
Table 84 RoW: Market, By Application, 20132020 ($Million)
Table 85 Collaborations/Agreements/Partnerships/Alliances, 2012-2015
Table 86 New Product Launches, 20122015
Table 87 Acquisitions, 20122015
Table 88 Expansions, 20122015
Table 89 Other Strategies, 20122015
 
 
List of Figures (37 Figures)
 
Figure 1 Cancer Diagnostics Market Segmentation
Figure 2 Global Cancer Diagnostics Market : Research Methodology Steps
Figure 3 Sampling Frame: Primary Research
Figure 4 Break Down of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Market Size Estimation Methodology: Bottom-Up Approach
Figure 6 Market Size Estimation Methodology: Top-Down Approach
Figure 7 Market Forecast Methodology
Figure 8 Data Triangulation Methodology
Figure 9 Platform-Based Diagnostics to Witness Highest CAGR of 25.3% From 2015 to 2020
Figure 10 Global Platform-Based Cancer Diagnostics Market Share, By Technology, 20152020
Figure 11 Global Cancer Diagnostics Market, By Geography
Figure 12 Largest and Fastest-Growing Cancer Diagnostic Applications, 2015-2020
Figure 13 Cancer Diagnostics Market Likely to Grow at A CAGR of 12.9% in the Forecast Period
Figure 14 Market, By Region and Application: North America Will Dominate the Cancer Diagnostics Market in 2015
Figure 15 Asia to Witness the Highest Growth Rate During the Forecast Period
Figure 16 Instrument-Based Technology Will Command Largest Market Share
Figure 17 Market: Drivers, Restraints, Opportunities, & Challenges
Figure 18 NGS, A Ground-Breaking Technology in Cancer Diagnosis
Figure 19 Ultrasound Accounted for the Largest Share of the Cancer Diagnostics Market for Imaging
Figure 20 Market Growth Will Be Driven By Rising Incidence & Prevalence of Breast and Lung Cancers
Figure 21 Lung Cancer Application is Expected to Grow at the Highest CAGR in the Forecast Period
Figure 22 New Product Launches Was the Key Growth Strategy for Market Players
Figure 23 Global NGS Market (For Cancer Diagnostics) Share Analysis, By Key Player, 2014
Figure 24 Global Microarrays Market (For Cancer Diagnostics) Share Analysis, By Key Player, 2014
Figure 25 Global Flow Cytometry (For Cancer Diagnostics) Market Share Analysis, By Key Player, 2014
Figure 26 Global MRI Imaging Market Share Analysis, By Key Player, 2014
Figure 27 Global CT Imaging Market Share Analysis, By Key Player, 2014
Figure 28 Global PET Imaging Market Share Analysis, By Key Player, 2014
Figure 29 Global Ultrasound Imaging Market Share Analysis, By Key Player, 2014
Figure 30 Battle for Market Share: Collaborations/Agreements/Partnerships/ Alliances Were Key Strategies
Figure 31 Becton, Dickinson and Company: Company Snapshot
Figure 32 GE Healthcare: Company Snapshot
Figure 33 Abbott: Company Snapshot
Figure 34 Roche Diagnostics: Company Snapshot
Figure 35 Illumina, Inc.: Company Snapshot
Figure 36 Siemens: Company Snapshot
Figure 37 C.R. Bard, Inc.: Company Snapshot

    The cancer diagnostics market is highly competitive with a large number of big and small players operating in different market segments. Based on technology, this market is categorized into platform-based and instrument-based. The instrument-based cancer diagnostics segment is expected to account for a major share of this market, by product, in 2015.

    Based on application, this market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, and others. Breast cancer is expected to account for a major share of the cancer diagnostics applications market in 2015.

    Technological advancements in various fields such as biomarkers, imaging, biopsy, and endoscopy; growing prevalence of cancer, rapid rise in aging population, increasing number of awareness initiatives by governments, and growing government funding. However, high capital investments and low benefit-cost ratio of biomarkers, and high cost of diagnostic imaging instruments pose restraints to the growth of this market. Improving healthcare infrastructure in emerging countries and growing demand of personalized medicines offer growth opportunities for this market.

    On the basis of regions, this market is classified into North America, Europe, Asia, and the Rest of the World (RoW).

    Global Cancer Diagnostics Market Size, by Region, 20152020

    Cancer Diagnostics Market

    Source: MarketsandMarkets Analysis

    The global cancer diagnostics market is expected to reach $13.1 Billion in 2020 from an estimated $7.1 Billion in 2015, growing at a CAGR of 12.9%. The market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). The cancer diagnostics market in Asia is expected to grow at the highest rate from 2015 to 2020.

    Some of the major players in the global cancer diagnostics market include Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (Denmark), Becton, Dickinson and Company (U.S.),  GE Healthcare (U.K.), QIAGEN N.V.  (Netherlands), Abbott Laboratories, Inc. (U.S.), Roche Diagnostics (Switzerland), Siemens Healthcare (Germany), Philips Healthcare (U.K.), and C.R. Bard, Inc. (U.S.).

    Custom Market Research Services

    We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

    Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

    Connect With Us

    Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
    Live Chat Support


    US : 1-888-600-6441
    UK : 44-800-368-9399

    Search reports



    Access reports on all high
    growth Medical Devices Markets on KnowledgeStore
    Request Demo Now